Mark Bachleda takes the helm at Eyconis

Ophthalmic therapies play Eyconis Inc. named Mark Bachleda CEO and board member. Bachleda was chief commercial officer at Galera Therapeutics Inc. (NASDAQ:GRTX) before which he was VP & U.S. business unit head of CAR T cell therapy franchise at Bristol Myers Squibb Co. (NYSE:BMY). Eyconis launched in January with ophthalmology assets from Ascendis Pharma A/S (NASDAQ:ASND) and $150 million committed capital from Frazier, RA Capital Management, venBio, and HealthQuest Capital.

Hematological disease company Disc Medicine Inc. (NASDAQ:IRON) hired Steve Caffé as chief regulatory officer. Caffé was head of regulatory affairs at CRISPR Therapeutics AG (NASDAQ:CRSP)...